Retatrutide Phase 3 Results: Breaking Down the TRIUMPH-

Eli Lilly's retatrutide program has produced the most dramatic weight loss data in the history of obesity pharmacotherapy. Two Phase 3 trials — TRIUMPH-4 and TRANSCEND-T2D-1 — reported results between December 2025 and March 2026, and the numbers are reshaping expectations for what pharmacological weight loss can achieve.

This article breaks down what each trial found, what the numbers mean in practice, and where the program goes from here.

TRIUMPH-4: The Landmark Obesity Trial

Design: Phase 3, randomized, double-blind, placebo-controlled. Adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity.

Key results (68 weeks):

• 12 mg dose: Average weight loss of 28.7% from baseline
• 8 mg dose: ~24% weight loss
• 2 mg dose: ~12% weight loss
• Placebo: ~1-2% weight loss

What 28.7% means in practice: For a 250 lb person, that's 71.75 lbs lost — dropping from 250 to 178 lbs over 68 weeks. That's roughly 1.2 lbs per week, sustained for over a year.

Critical finding: Weight loss continued through 68 weeks without plateau. With semaglutide, weight loss typically plateaus around week 40-48. Retatrutide's triple mechanism — particularly the glucagon-driven energy expenditure — appears to sustain the caloric deficit even as the body tries to adapt.

Body composition: Fat mass reduction of up to 26.1% at 8 mg over 36 weeks (Phase 2 data). Lean mass was also reduced, proportional to total weight loss.

TRANSCEND-T2D-1: Diabetes Focus

Design: Phase 3 trial in adults with type 2 diabetes. 40-week primary endpoint.

Key results:

• Weight loss: 16.8% on retatrutide vs. 3.3% on placebo
• HbA1c reduction: Significant (exact percentage not yet fully published)
• Notable because: Diabetics typically lose less weight on GLP-1 agonists than non-diabetics. 16.8% is substantially more than semaglutide achieves in diabetic populations (~10-14%).

Clinical significance: If approved, retatrutide could become the preferred weight loss medication for type 2 diabetes patients — a population that currently has fewer effective options than non-diabetics.

Cardiovascular Risk Markers

Both trials showed improvements in cardiovascular risk markers:

• Non-HDL cholesterol: significant reduction
• Triglycerides: significant reduction
• hsCRP (high-sensitivity C-reactive protein, an inflammation marker): reduced
• Blood pressure: up to 14 mmHg systolic reduction
• Liver fat: up to 86% reduction

Dedicated cardiovascular outcome trials are ongoing. The Phase 3 TRIUMPH-4 data suggests a favorable cardiovascular profile, but a dedicated CVOT is needed before making claims about cardiovascular event reduction.

Safety and Tolerability

The Phase 3 safety profile was consistent with Phase 2:

• Gastrointestinal effects (nausea, diarrhea, vomiting) were the most common adverse events
• Dysesthesia (skin tingling/burning) at higher doses
• Heart rhythm changes in ~6% of retatrutide patients
• Injection site reactions
• Gradual dose titration reduced GI effects

Serious adverse events were comparable between retatrutide and placebo groups.

What's Next

Eli Lilly has seven additional Phase 3 trials ongoing:

• TRIUMPH-3: OSA (obstructive sleep apnea)
• TRIUMPH-2: Knee osteoarthritis
• TRANSCEND-T2D-2 and -3: Additional diabetes populations
• TRANSCEND-Obesity-1 and -2: Extended obesity trials
• CVOT: Cardiovascular outcomes

FDA NDA submission is expected Q4 2026 or Q1 2027. If the timeline holds, retatrutide could reach market by late 2027.

The Bottom Line

28.7% weight loss is a number that changes the conversation. It approaches the results of bariatric surgery (25-35% depending on procedure) without the surgical risk. For fitness professionals, this means preparing now for a future where clients may arrive having lost 50-70 lbs pharmacologically, with significant body composition challenges to address.

References

1. Jastreboff, A.M., et al. (2023). Phase 2 Trial. NEJM, 389(6), 514-526. DOI: 10.1056/NEJMoa2301972
2. TRIUMPH-4 Phase 3 Results. Eli Lilly (December 2025).
3. TRANSCEND-T2D-1 Phase 3 Results. Eli Lilly (March 2026).
4. ClinicalTrials.gov — Retatrutide Phase 3 program.

This article is for informational purposes only and does not constitute medical advice.